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ABSTRACT 
Nasopharyngeal carcinoma (NPC) is a rare malignancy worldwide, but it is endemic in a few 
areas including southern China, Southeast Asia, North Africa, and the Arctic. The underlying 
mechanisms behind this remarkable geographic distribution remain unclear. Although 
Epstein-Barr virus (EBV) infection has been suggested as a necessary cause of 
undifferentiated NPC, EBV itself is not sufficient to cause this malignancy. Other co-factors, 
such as environmental risk factors, and/or genetic susceptibility, may interact with EBV to 
play a role in the carcinogenesis of NPC.  
Survival rates differ significantly between NPC patients in early stages and late stages. Due to 
the close associations between EBV infection and NPC risk, EBV-related biomarkers have 
been used for early detection and screening for NPC in a few high-incidence areas. However, 
the cost-effectiveness of this approach has not been demonstrated. Pilot efforts have 
highlighted that identification of additional biomarkers is needed to improve the early 
detection rate and reduce the mortality rate of NPC in high-incidence populations. The aim of 
this thesis is to study the association of early-life social environment, oral hygiene, and family 
history with the risk of NPC, and to utilize an affinity proteomic approach to identify 
biomarkers that can potentially facilitate the early detection.  
In Study I, we investigated associations between childhood family structure, in terms of 
sibship size and number of older/younger siblings, and the risk of NPC or infectious 
mononucleosis (IM, another EBV-associated disease) in Sweden, an NPC low-incidence 
area. For each outcome, a nested case-control study was conducted within the Swedish 
national health and population registers, including 251 NPC cases, 11,314 IM cases, and five 
population controls per case matched by sex and year of birth. Clearly contrasting findings 
were observed between NPC and IM risk. We detected a monotonically increased risk of 
NPC with a larger sibship size (P trend = 0.006), especially with an increasing number of older 
siblings. For example, the odds ratio (OR) of NPC for those with three or more siblings 
compared with no siblings was 2.03 (95% confidence interval [CI]: 1.23, 3.35). In contrast, 
we detected a lower risk of IM among subjects with a larger sibship size, and more 
older/younger siblings. We concluded that early-life social environment could contribute to 
NPC pathogenesis in non-endemic areas. Earlier infection with EBV might be associated 
with an elevated risk of NPC, which is further supported by the clearly contrasting findings 
between NPC and IM.   
In Study II, we estimated the associations between oral hygiene and NPC risk in a high-
incidence area. We conducted a population-based case-control study in southern China 
between 2010 and 2014, with a total of 2528 newly diagnosed NPC cases aged 20-74, and 
2596 randomly selected controls. Controls were frequency matched to the age and sex 
distribution of the cases by geographic region. Based on questionnaire information, we found 
an increased risk of NPC with a higher number of filled teeth. Compared with those having 
no filled teeth, subjects having 1 to 3 and more than 3 filled teeth had adjusted ORs of 1.25 
(95% CI: 1.06, 1.49) and 1.55 (95% CI: 1.13, 2.12), respectively (P trend = 0.002). In contrast, 
more frequent tooth brushing was inversely associated with the risk of NPC. We concluded 
that poor oral health could be associated with an elevated risk of NPC. Prospective cohort 
studies with a comprehensive measurement on oral health condition are needed to confirm 
our findings and explore the underlying mechanisms.  
Absolute NPC risks in the general population with and without a family history of NPC in 
NPC-endemic geographic regions, where the great majority of NPC cases occur worldwide, 
are largely unknown. In Study III, we utilized family data from the aforementioned 
population-based case-control study in southern China and found that subjects with a first-
degree family history of NPC were at a greater than 4-fold higher risk for NPC, compared to 
those without such a history, whereas a family history of other malignancies did not confer an 
increased risk of NPC. The excess risk was higher for a maternal than a paternal history and 
slightly stronger for a sibling than a parental history, and for a sororal than a fraternal history. 
Among first-degree relatives of cases, the cumulative risk of NPC up to age 74 years was 
3.7%, whereas that among relatives of controls was 0.9%. Cumulative risk was higher in 
siblings than in parents among relatives of cases, whereas no such difference was noted 
among relatives of controls. 
The affinity proteomic approach is valuable for biomarker validation and identification. In 
Study IV, we utilized plasma samples from 174 NPC cases and 175 community-based 
controls from Taiwan to identify biomarkers that could potentially facilitate early detection of 
NPC. We established a panel of eight such biomarkers, including proteins encoded by the 
genes CCNB1, KDR, PDGFB, LGALS1, HAS1, LY6K, IL2RA, and CXCL10. The 
combination of these eight markers showed promising value to distinguish early-stage NPC 
patients from controls (areas under the receiver operating characteristic curves = 0.808, 95% 
CI: 0.745, 0.871). Additional studies with prospectively collected biospecimens are warranted 
to examine the use of these plasma biomarkers in the early detection of NPC.  
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1 INTRODUCTION 
Nasopharyngeal carcinoma (NPC) is one of the Epstein-Barr virus (EBV)-associated 
malignancies, characterized by a remarkable geographical distribution. It is a major cause of 
morbidity and mortality in southern China, where it is one of the most common cancers. 
Despite the heavy public-health burden of NPC in southern China and other endemic areas, 
relatively little is known about the etiology and prevention of NPC. Although certain 
environmental exposures, including high consumption of salt-preserved fish and other 
preserved foods, low consumption of fresh fruits and vegetables, and tobacco smoking, are 
generally well accepted as NPC risk factors, to date there has been no rigorous population-
based case-control study of NPC in southern China. Evidence accumulated so far indicates a 
probable causal role of EBV in the pathogenesis of undifferentiated NPC (the most common 
histological subtype of NPC). However, despite establishing lifelong latency in the majority 
of humans, only a small proportion of individuals infected with EBV develop cancer. This 
indicates that EBV alone is not a sufficient cause for this malignancy. Environmental 
exposures and/or genetic risk factors likely also play a role in the pathogenesis of this tumor.  
Despite the unknown etiology, using antibodies against EBV for early diagnosis and 
screening for NPC has been conducted in a few high-incidence areas in southern China since 
the 1970s. Traditional markers include IgA antibodies against EBV capsid antigen 
(VCA/IgA) and early antigen (EA/IgA) measured by immunofluorescence assays. Recent 
studies demonstrated that a combination of IgA antibodies against the Epstein-Barr nuclear 
antigen1 (EBNA1/IgA) and VCA/IgA measured by enzyme-linked immunosorbent assay 
(ELISA) has higher sensitivity, specificity, and positive predictive value compared with the 
traditional method. Individuals identified as being at high risk of NPC based on EBV 
serological markers can be offered fiberoptic endoscopy/biopsy and close medical 
surveillance to enable early diagnosis of NPC and, ideally, reduced mortality. However, the 
cost-effectiveness of this labour-intensive strategy has yet not been proved, and new 
biomarkers are needed more specifically identify the high-risk population, in order to provide 
screening for NPC in the general population. 
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2 BACKGROUND 
2.1 DESCRIPTIVE EPIDEMIOLOGY 
 
Figure 1 Global nasopharyngeal carcinoma incidence: estimated age-standardized 
incidence rate per 100,000, both sexes, all ages. Source: GLOBOCAN 2012 (IARC) 
Worldwide, NPC is a rare malignancy, with an incidence rate of generally <1 per 100,000 
person-years, but areas of the high incidence are in regions of southern China, Southeast 
Asia, North Africa, and the Arctic [1] (Figure 1). In 2012, ~ 86,000 incident cases of NPC 
were diagnosed worldwide and the estimated number of deaths exceeded 50,000, making it 
the 24th most common new cancer in the world; in contrast, NPC was the 7th most common 
new malignancy in Southeast Asia [1]. Other areas with incidence rates ranging from 5 to 15 
per 100,000 person-years, exist in northern China, the Middle East and Mediterranean, and 
North Africa, and among the Inuit of Alaska and Greenland [1]. In some parts of southern 
China, where NPC is endemic, NPC was the 3rd most common new malignancy in males in 
cities of Guangzhou, Zhongshan, and Sihui [2]. The overall age-standardized incidence rates 
in these areas are >20 per 100,000 person-years among males, which are more than100-fold 
higher than the rest of the world.  
The World Health Organization (WHO) classification divides NPC into four 
histopathological types: keratinizing squamous cell carcinoma (type I), differentiated 
nonkeratinizing carcinoma (type II), undifferentiated nonkeratinizing carcinoma (type III), 
and basaloid squamous cell carcinoma [3, 4]. In NPC endemic areas, over 90% of NPC cases 
in endemic areas are type III and most of the remaining 10% is type II [5]; On the other hand, 
~ 50% of cases in non-endemic areas are type I [6, 7]. Type I appears to have different risk 
factors and pathogenic processes compared to types II/III NPC [8]. For example, gene 
products of Epstein-Barr virus (EBV) are detected in the tumor cells of all type III NPC [9, 
10], whereas the role of EBV infection on the etiology of type I remains uncertain. Cigarette 
smoking and alcohol drinking account for >50% of type I NPC in non-endemic areas, 
whereas they are much more weakly associated with types II and III NPC [7, 11]. Basaloid 
squamous cell carcinoma, a new histopathological subtype introduced in 2005, is very rare in 
high-incidence areas and morphologically is the same as the same tumor elsewhere in the 
head and neck region [4]. 
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Despite the decreasing incidences of NPC in some areas of Southeast Asia, such as Taiwan 
[12], Hong Kong [13], Singapore[13], and Sweden (Figure 2A), the secular trend was stable 
in high-risk areas of southern China over the last 20 years (Figure 2B) [14, 15] . Of note, the 
decreased incidence was found only for type I NPC whereas the incidence of type II/III NPC 
remains stable in Hong Kong [16]. The overall decline in incidence of type I NPC may be 
attributed to the consequences of economic development in Hong Kong (e.g. decline in 
smoking), whereas the relatively steady in incidence of type II/III NPC may be attributed to 
the interplay of genetics, virus infection, and/or stable environmental exposures.   
 
 
Figure 2 Age-standardized incidence rates (world) of nasopharyngeal carcinoma among 
males and females.  
A. Sweden (1970-2015); data was downloaded from Socialstyrelsen: 
http://www.socialstyrelsen.se/statistics/statisticaldatabase/cancer 
B. Sihui, Guangdong Province, China (1987-2011); reproduced from [15] 
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In both NPC-endemic and non-endemic areas, age-standardized incidence rates are 
consistently 2- to 3-fold higher in males than in females [17]. A bimodal pattern of age 
distributions in low-incidence populations has been observed, with an initial peak in early 
adulthood, followed by a second peak later in life [18]. In contrast, the peak of incidence is 
around ages 45 to 59 years in high-incidence populations [14], apparently highlighting the 
importance of early exposure to carcinogens, such as childhood environmental factors and 
genetic predisposition, is essential in the etiology of type II/III NPC [14, 17]. 
2.2 CLINICAL FEATURES 
The symptoms and signs at presentation of NPC include neck masses, epistaxis, nasal 
obstruction and discharge, headache, and other nonspecific indicators. Furthermore, because 
the cancer is located in a silent anatomic site (Figure 3), and NPC exhibits a higher 
metastatic rate compared to other head and neck cancers [19], NPC tends to present at 
advanced stages (clinical stages III and IV) when diagnosed. It has been shown that >70% of 
patients were at advanced stage when diagnosed in clinics [20]. A 10-year survival rate for 
NPC patients can reach 98% for stage I and 60% for stage II [21]. In contrast, median 
survival is 3 years for patients at advanced stages [22], highlighting that to improvements in 
diagnosis rate could help to reduce NPC mortality.  
 
Figure 3 Anatomy of the head and neck  
(Source: http://www.cancer.gov/types/head-and-neck) 
 
Especially in high-incidence area, patients with symptoms should be clinically assessed for 
physical signs of the disease. The examination of the nasopharynx is firstly made by an 
indirect nasopharyngoscope, followed by a direct nasopharyngoscope (fiberoptic endoscope). 
A biopsy should be performed if a suspicious growth of in the nasopharynx (e.g. an elevated, 
nodular, rough, or ulcerative nasopharyngeal surface) is detected. Cross-sectional imaging by 
computed tomography (CT) scan or magnetic resonance imaging (MRI) should be 
undertaken even if a suspected tumor is not visualized with endoscopic examination.  
2.3 RISK FACTORS 
Since the malignancy was firstly reported in 1901 [23], the etiology of NPC has remained a 
puzzle for more than a century. Migrant studies show that when southern Chinese settle in 
other countries, their incidence of NPC is 10 to 30 times higher than that of other races – a 
rare pattern among malignancies suggesting a strong genetic component of NPC risk [24, 25]. 
  5 
A higher incidence of NPC is also observed among North African immigrants in Israel and 
Sweden, when compared to the native Israelis and native Swedes [24, 26]. Incidence of NPC 
among Chinese born in western countries is still higher than that among Caucasians, although 
it is about half that of those living in China or migrating within Southeast Asia [27-29]. In 
addition, compared with those born in southern France, men of French origin born in North 
Africa also had a higher incidence of NPC [30]. The latter findings indicate that in addition to 
genetics, environmental factors also play an important role in NPC. 
To date, established risk factors for type III NPC include Cantonese ethnicity [31], male sex 
[31, 32], EBV infection [10], a family history of NPC [33-36], high consumption of salt-
preserved fish [37], low intake of fresh vegetables and fruits intake [38, 39], smoking [40], 
and some human leukocyte antigen (HLA) class I alleles [41-43]. On the other hand, other 
HLA genotypes [44] and a history of infectious mononucleosis (IM) [7, 45, 46] may be 
associated with a decreased risk. Further potential risk factors include high consumption of 
other preserved foods [38, 47, 48], a history of chronic respiratory tract conditions [49, 50], 
and genetic polymorphisms in cytochrome P450 2E1 (CYP2E1), CYP2A6, glutathione S-
transferase M1 (GSTM1), and GSTT1 [51]. Less established risk factors include consumption 
of herbal medicine, occupational exposures to dust and formaldehyde, and nickel exposure 
[17, 52]. This thesis focuses on two unexplored risk factors (i.e. early family structure and 
oral hygiene), and quantification of familial risk of NPC in a high-incidence area of southern 
China.    
2.3.1 Epstein-Barr Virus (EBV)  
EBV, a gamma-herpesvirus that infects lymphocytes and epithelial cells, establishes lifelong 
latency in more than 90% of adults globally [53-55]. Primary infection with EBV usually 
occurs early in life and transmission is mainly through saliva. In high NPC incidence areas, 
such as Hong Kong, Taiwan, and mainland China,  ~60% of children have been infected by 
age 2, ~80% by age 6, and almost 100% by age 10 [56-58].  In contrast, age at primary 
infection is relatively late in children from western countries, such as US, Denmark, and 
Sweden [55, 59, 60]. Although primary infection with EBV is usually asymptomatic, it is 
associated with certain diseases, including IM and Burkitt’s lymphoma (BL), ~30% of HL, 
certain subtypes of non-Hodgkin lymphoma, type III NPC, and a subset (~10%) of gastric 
carcinoma [61]. It is estimated that ~143,000 deaths worldwide in 2010 could be attributed to 
EBV-associated malignancies [62]. 
The link between EBV and NPC was first proposed in 1966 when NPC patients were 
reported to have higher titers of antibodies against an antigen later demonstrated as a product 
of EBV [63]. Since then, extensive evidence suggests that EBV is a potential cause of NPC, 
especially type III [10]. First, monoclonal EBV genome and viral gene products are detected 
in virtually all tumors in NPC-endemic areas [63-67], indicating that the tumors result from 
clonal proliferations of a single cell that is initially infected with EBV. Second, elevated IgA 
antibodies against EBV antigens are highly specific markers for subsequent NPC in high-
incidence areas [68, 69], while elevated EBV-neutralizing antibodies blocking B-cell 
infection and anti-gp350 antibodies are inversely associated with NPC risk [70]. Third, the 
expression of viral proteins, such as latent membrane protein 1 (LMP1), LMP2, Epstein-Barr 
nuclear antigen1 (EBNA1) and EBNA2, has been demonstrated to drive tumor progression in 
invasive epithelial cancers [10]. Nevertheless, EBV has never been detected in non-cancerous 
epithelial cells of the nasopharynx [71], and epithelial infection is much less efficient in vitro 
than B-lymphocyte infection [72]. The viral target, complement receptor type 2 (CR2), which 
is presented on B cells and attaches to EBV envelop, gp 350/220, is expressed at low levels 
on epithelial cells (Figure 4) [73, 74]. Therefore, other mechanisms of viral entry into 
epithelial cells have been postulated [75], including attachment to two additional 
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glycoproteins, gHgL and gB (Figure 5) [76], cell-to-cell contact [77, 78], or IgA/secretory 
component (SC) protein mediation [79].  
 
Figure 4 A putative model of the steps involved in entry of EBV into a B lymphocyte. 
(Adapted from Hutt-Fletcher LM [74])  
 
Figure 5 Putative models of the steps involved in entry of EBV into epithelial cells after 
attachment via different cell proteins. (Adapted from Hutt-Fletcher LM [74]) 
2.3.2 Early-Life Risk Factors 
Factors that could potentially alter the oncogenicity of EBV include the age and immune 
response at the time of primary EBV infection [46, 80]. For example, when primary infection 
is delayed until adolescence, the EBV-related immune response is robust and can lead to 
symptoms of IM, which is linked to risk of EBV-related HL in adulthood [81-83]. In NPC-
endemic areas, IM and HL are not prevalent, leading us to hypothesize that timing at 
infection may play a role in the development of NPC. Accumulated evidence shows that 
childhood exposure to certain environmental factors confer a higher risk of NPC [84, 85]. 
Nevertheless, the associations of factors influencing the timing of common childhood 
infections with the risk of NPC have not been studied. There are a few studies showing that a 
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history of IM is associated with a lower risk of NPC [7, 45, 46], although commonly based on 
small number of cases. In high-risk populations, perhaps due to the fact that late infection is 
rare, it is difficult to estimate the association between a history of IM and NPC risk [46]. In 
NPC non-endemic areas, however, the rarity of NPC makes the evaluation of this hypothesis 
a big challenge.   
The household environment during childhood, when primary EBV infection is most probable, 
including number of siblings and population density of the household, could be important 
predictors for the immunological control of EBV and eventual EBV-related disease risk [86].  
Childhood family structure may serve as an indirect indicator of early infection with common 
childhood pathogens. For example, birth order has been linked to risk of other EBV-related 
malignancies, such as HL [87, 88], and also to hepatocellular carcinoma [89, 90]. Hence, we 
hypothesized that very early exposure to EBV and other carcinogens may play a role in NPC 
pathogenesis. Studies on early childhood family structure may lend insights into whether 
timing of primary infection with EBV is associated with a subsequent risk of NPC. 
2.3.3 Oral Hygiene 
Poor oral health, as a modifiable risk factor that is common among the elderly [91-94], has 
been linked to cancers of the pancreas, esophagus, stomach, and head and neck [95-104]. In 
the case of NPC, periodontitis might increase inflammation [105, 106] and thus might 
increase the risk for NPC, given that inflammatory response could be one pathway of 
carcinogenesis promotion [61, 107, 108]. In addition, bacterial load increases with a greater 
number of teeth lost [109], and some of the bacteria have been implicated in the production of 
nitrosamines, which are known carcinogens for NPC development [110, 111]. Poor oral 
health could also increase the risk of NPC by stimulating EBV replication, as indicated by 
higher viral load among individuals with periodontal disease than those without [112-116]. In 
rats, n-butyrate produced by anaerobic bacteria found in the nasopharynx, combined with 
phorbol ester (TPA)-like plant and soil microelements, can enhance EBV-mediated B-cell 
transformation and promote NPC development [117]. The proposed underlying mechanistic 
pathways are demonstrated in Figure 6. 
 
 
 
 
 
Figure 6 Hypothetical underlying mechanistic pathways linking poor oral hygiene with 
NPC risk  
Few epidemiological studies have tried to address this research question of whether poor oral 
hygiene is related to NPC risk. One hospital-based case-control study in Turkey showed that 
infrequent tooth brushing and an increasing number of decayed teeth were associated with a 
higher NPC risk [118]. Compared with those who brushed teeth daily, those who teeth 
brushed rarely had an odds ratio (OR) of 6.17 (95% CI: 3.60, 10.55). However, when 
examining poor oral health as a risk factor for cancer in general, any positive associations 
could be due to residual confounding by smoking, low socioeconomic status, diet, and/or 
medical history. Detailed risk factor information in a large, population-based case-control 
study could help to facilitate the rigorous evaluation of oral health as a risk factor for NPC. 
Chronic inflammation 
EBV  Poor oral hygiene 
Bacterial overgrowth 
NPC 
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2.3.4 Familial Aggregation 
Familial clustering has been consistently reported in NPC high-incidence [119-122], 
intermediate-incidence [34, 123, 124], and low-incidence [125, 126] areas. In southern 
China, where NPC is endemic, more than 5% of incident cases reported a positive family 
history of NPC among the first-degree relatives [122, 127, 128]. Previous case-control 
studies in different populations showed that ORs ranged from 2 to 20 in individuals who 
reported a first-degree family history of NPC compared with those with no such history 
[48, 122, 123, 127, 129-135]. This magnitude of association is among the highest of any 
malignancy [136], suggesting that environmental factors themselves cannot fully explain 
the observed association. A cohort study in Taiwan showed that the risk of NPC among 
males in a multiplex family cohort was 6.8-fold higher than that in a community cohort 
[35]. Genes and environmental exposures likely play a combined role in the etiology of 
NPC [17]. An inheritance pattern that cannot be explained by activation of a single 
major susceptibility gene is supported by results from a complex segregation analysis of 
familial NPC showing that the etiology of NPC involves interaction of multiple genetic 
and environmental factors [137].  
Whether familial NPC cases differ substantially from sporadic cases in terms of clinical 
features (i.e. histology, stage, and prognosis), ethnicity, sex, age at diagnosis, 
environment risk factors, EBV serology, and/or genetic risk factors is still controversial. 
A few studies showed that familial cases did not have characteristics notably distinct 
from sporadic cases [119, 129, 130, 138]. On the other hand, others found that familial 
NPC cases tend to be younger [139-141], and have better survival than sporadic cases 
[141, 142]. Three previous studies reported significant modification of the association 
with family history of NPC by smoking [133], wood fuel use [143], and salt-preserved 
fish consumption [122], whereas a prospective study did not find an interaction between 
smoking and family history of NPC [35]. The small number of controls with a positive 
first-degree family history of NPC and the low power of the statistical test of 
heterogeneity make it difficult to draw firm conclusions about the joint effects of family 
history and environmental risk factors. Pooled studies with larger numbers of subjects 
will enable more powerful tests of such interactions. 
To date, previous epidemiologic studies of NPC have been limited in number, size, 
scope, and rigorousness of study design. Few studies have investigated the relative-
specific risk among families with affected members. Because most studies have not 
ascertained all first-degree relatives and are not population-based, absolute NPC risks in 
the general population with and without a family history in NPC-endemic geographic 
regions, where the great majority of NPC cases occur worldwide [2], are largely 
unknown. The lack of evidences precludes cost-effectiveness modeling of screening for 
NPC among families with a positive history of NPC.  
2.3.5 Genetic Susceptibility 
As reviewed by Hildesheim and Wang [51], since 2000, a total of 83 published papers have 
investigated genetic risk factors for NPC. Only one genome-wide association study (GWAS) 
utilized samples from more than 1000 cases and controls [144]; other GWAS were limited to 
a few hundred cases and controls. A number of genetic polymorphisms associated with NPC 
risk have been identified, including classical HLA class I/II genes, non-classical HLA genes, 
phase I/II metabolic activation/detoxification and DNA repair genes, and other genes such as 
those involved in cell cycle control, cell adhesion/migration, angiogenesis, and DNA 
methylation. 
  9 
Many investigators have focused on the possible pathogenetic role of HLA molecules, which 
are required for the presentation of foreign antigens, including viral peptides, to the immune 
system for targeted lysis. In Chinese and other high-risk Asian populations, HLA-A2-B46, 
and B17 are associated with a 2- to 3-fold increase in NPC risk, whereas an increased risk is 
associated with HLA-B5 in Caucasians. One-third to one-half lower risk is found in 
association with HLA-A11 across all races, B13 in Chinese and Tunisians, and A2 in non-
Chinese. Several other HLA associations have been reported, but must be interpreted with 
caution due to multiple-testing considerations [44]. Genetic polymorphisms other than HLA 
are also reported. However, most genetic association studies are based on small sample sizes, 
and the lack of replication precludes a full understanding of genetic influences on NPC 
development. 
2.4 SCREENING  
2.4.1 Screening in High-incidence Areas 
The notion that testing for antibodies against EBV could a useful screening tool to facilitate 
the early detection of NPC is supported by several lines of evidence. First, EBV infection is 
an early event during the tumor progression [67], and the EBV genome and gene products 
can be detected in virtually all tumors of type III NPC [63-67]. Second, VCA/IgA [35, 68, 
69], neutralizing antibodies against EBV DNAse [35, 68], and EA/IgA [145-149], can be 
detected in serum even years prior to clinical evidence of the cancer, making them the basis 
for successful NPC screening tests in high-incidence areas. A few pilot efforts have been 
made to conduct NPC mass screening in high-incidence counties in southern China since the 
1970s [145], using the two biomarkers of VCA/IgA and EA/IgA measured by 
immunofluorescence assays. More recently, studies in southern China demonstrated that a 
combination of EBNA1/IgA and VCA/IgA measured by enzyme-linked immunosorbent 
assay (ELISA) had a higher diagnostic accuracy (i.e. high sensitivity, specificity, and positive 
predictive value [PPV]) in both the general population [150] and families with at least two 
affected relatives [148].  
Although the value of using antibodies against EBV to facilitate NPC diagnosis is generally 
accepted, there are a few barriers to the implementation of screening for NPC by testing these 
antibodies in high-incidence populations. First, only a fraction of the ~2% of individuals with 
elevated titers of VCA/IgA in high-risk areas develop NPC [68, 69]. As shown by one of our 
large cohort studies in Sihui, southern China, after 20 years of follow-up, only 42 NPC cases 
were found among 1318 individuals who were positive for VCA/IgA at baseline [69]. Our 
results from an initial round of screening showed that anti-EBV antibodies can increase the 
early diagnosis rate to ~70% but with low PPV (~3%) [128]. Second, serologic evidence of 
EBV reactivation from latency, as indicated by elevated antibody titers against viral lytic 
antigens, can also be detected in normal individuals, particularly during periods of 
psychological or physical stress [151, 152], thereby decreasing their specificity. Third, 
previous efforts were not carefully controlled (i.e. no randomized controlled trial has yet been 
conducted) and do not permit accurate quantification of the impact of EBV-based screening 
on detection rates of early-stage NPC and on NPC mortality. These results are required to 
support evidence-based decisions regarding the efficacy and cost-effectiveness of such 
screening strategies.   
2.4.2 Search for Novel Biomarkers for Early Detection  
Other than biomarkers related to EBV, biomarkers related to the human proteome may also 
exhibit great potential for early diagnosis of NPC. A handful of studies have used proteomics 
to investigate potential biomarkers for early diagnosis of NPC [153]. Although a number of 
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biomarkers have been identified, few have been replicated in other independent studies. Most 
of them may have biological implications rather than diagnostic capacity. Limited sample 
size, inappropriate study design, heterogeneity of NPC, and different technologies used 
across different studies may contribute to the inconsistency of findings.  
To date, the technology most commonly used for human protein biomarker discovery is mass 
spectrometry (MS), which is limited to the analysis of a relatively small number of samples in 
parallel [154]. Recently, plasma antibody profiling technologies, such as antibody suspension 
bead array assays [155, 156], have been developed for multiplex screening of a large number 
of proteins in patient cohorts (Figure 7). This advance might bring a hope to identify and 
validate biomarkers for early diagnosis of NPC.  
 
Figure 7 Schematic view of bead array assay (adapted from Schwenk JM, et al. [156]) 
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3 AIMS 
The overall aim of this thesis was towards identification of risk factors and early diagnostic 
biomarkers for NPC 
The specific study aims were: 
• To examine the association between early childhood family structure and the risk of 
NPC in a low-incidence area.  
 
• To study the association of oral hygiene with risk of NPC in a high-incidence area 
based on a large, population-based case-control study in southern China. 
 
• To explore familial risks of NPC in detail and to quantify the lifetime risk of familial 
NPC in a high-incidence population. 
 
• To identify potential biomarkers for early diagnosis of NPC by using affinity 
antibody suspension bead array assays. 
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4 MATERIALS AND METHODS 
4.1 DATA SOURCES AND COLLECTION  
4.1.1 Swedish Multi-Generation Register 
The familial data from the Swedish Multi-Generation Register includes all residents born in 
1932 or later in Sweden, together with their parents (biological or adoptive) [157, 158]. Such 
information was available for 60% of individuals who died between 1968 and 1990, and for 
more than 95% of residents in Sweden alive in 1991 or deceased before 1968. Although 
information on individuals who died before 1991 were not available, almost 100% of 
individuals deceased before 1968 and ~60% of individuals deceased between 1968 and 1990 
can be identified from Statistics Sweden’s register of births and other personal records. All 
supplementary information is now included in the Register. 
4.1.2 Swedish Cancer Register 
In 1958, the Swedish Cancer Register was established and is now considered approaching 
98% complete [159]. In Sweden, it is mandatory for each health care provider to report newly 
diagnosed cancer cases from different resources, including clinical examinations, 
morphological analyses, laboratory tests, and autopsies. Information includes demographics 
(i.e. personal identification number, sex, age, and location of residence) and medical and 
follow-up data. Important medical information includes diagnosis (as indicated by the 7th 
edition of International Classification of Disease [ICD-7] through the whole period), date of 
diagnosis, histological type (old histology code – WHO/HS/CANC/24.1 – is available 
through the whole period), and stage (since 2004). The ICD-7 code “146” was used for NPC 
diagnosis in this Register.  
4.1.3 National Patient Register 
In the mid-1960s, the Swedish Patient Register was established by the National Board of 
Health and Welfare. It included only inpatient information from public hospitals in a few 
counties at the beginning. It has had nearly complete nation-wide coverage of somatic and 
psychiatric hospital inpatient discharges since 1987, and has also covered nation-wide 
outpatient care since 2001 with approximately 80% coverage [160]. Diagnoses are reported 
to the National Patient Register using the ICD-7 between 1961 and 1968, ICD-8 between 
1969 and 1986, ICD-9 between 1987 and 1996, and ICD-10 since 1997 [160].  
4.1.4 Other Registers 
In 1960, 1970, 1980 and 1990, Swedish nationwide censuses were conducted respectively 
[161]. This population with cross-linkage to the Swedish Multi-Generation Register was our 
study population for Study I. Parental region of residence and occupation were assembled 
from these Censuses. Emigration and death information for censoring was collected from the 
Emigration and Immigration Register and Cause of Death Register. 
4.1.5 Population Based Case-Control Study in Southern China 
In 2010, we launched a population based case-control study in southern China, where NPC is 
endemic. The collaborative NPC Genes, Environment, and EBV study (NPCGEE) was 
conducted in the Zhaoqing area of Guangdong Province and the Wuzhou and 
Guiping/Pingnan areas of Guangxi Autonomous Region. We defined the study base as 
persons living in 13 cities/counties (Deqing, Fengkai, Gaoyao, Huaiji, Sihui, Zhaoqing, 
Guangning, Wuzhou, Cenxi, Cangwu, Tengxian, Pingnan, and Guiping) between March 
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2010 and December 2013 for cases, and between November 2010 and November 2014 for 
controls. These 13 cities/counties were chosen because of their high incidence of NPC, their 
geographic contiguity, their existing opportunities for collaboration with local investigators, 
and their relatively stable population base compared with other, more urban areas in this 
geographic region. The total population of the 13 study cities/counties is approximately 8 
million and the estimated total number of incident NPC cases is approximately 850 per year, 
based on information from local cancer registries located in Sihui and Cangwu Counties [14]. 
To ensure adequate statistical power to detect interactive risk factors, we initially aimed to 
recruit 2,600 cases and 2,600 controls. 
Patients with incident cases of histologically confirmed NPC were recruited. We developed a 
rapid case ascertainment system involving a network of physicians who diagnosed and/or 
treated NPC at hospitals in the study area (Figure 8). Contact persons notified the study 
personnel as soon as a new NPC case was histopathologically confirmed, after which 
physician permission was sought to contact each patient, as long as the physician deemed the 
patient physically and mentally able to participate in the study. This rapid case ascertainment 
system was backed up by two population-based cancer registries that have collected cancer 
incidence data in Sihui County since 1977 and Cangwu County since 1982 [14]. However, 
these registries do not cover the entire population of the study area and are often not 
immediately notified about new cancer diagnoses, making them insufficient on their own to 
fulfill the aims of our study. Therefore, ad-hoc case ascertainment networks based on local 
hospitals are required for population-based case identification in most of parts of the areas.  
 
Figure 8 Participating hospitals and cancer research institutions 
Controls were randomly selected every 6–12 months from total population registries located 
in Guangdong Province and Guangxi Autonomous Region, with frequency matching to the 
expected 5-year age and sex distribution of the cases by residential areas. We first attempted 
to contact controls by village doctors in rural areas or community committee members in 
urban areas. Interviews were conducted at the subject’s home or a nearby hospital. Potential 
controls with outdated contact information or a history of working outside of the study area 
for more than 10 years, as identified with the help of the local government in each town or 
community, were replaced. 
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Structured, computerized questionnaire was administered to subjects in person by trained 
interviewers in the hospital or at home, as appropriate. Interviews were audiotaped for quality 
control, and logic checks and automatic skip patterns were built into the questionnaire. 
Preliminary questionnaire data were analyzed periodically to ensure that results were within 
expectation. The questionnaire covers potential NPC risk factors, including socioeconomic 
background, race/ethnicity, residential history, occupational history, smoking habits, alcohol 
consumption, herbal medicine use, medical history, reproductive history, family history of 
cancer, and past diet (i.e. 10 years ago at interview, adolescent, and childhood). After the 
interviews, biospecimens including blood, saliva, hair and nails were also collected. 
4.1.6 Community Based Case-Control Study in Taiwan 
Between July 15, 1991 and December 31, 1994, a community based case-control study was 
conducted in Taipei City, Taiwan, an NPC intermediate-incidence area. Incident cases of 
histologically confirmed NPC were recruited from the National Taiwan University and 
MacKay Memorial Hospitals, two large referral hospitals in Taipei. Eligible patients were 
less than aged 75 years, had had no prior diagnosis or treatment for NPC, and had resided in 
Taipei city or county for 6 months or longer. For each case, one control was selected 
individually matching on sex, 5-year age, and residence area (same district or township). 
Controls were those without a history of NPC before selection in the study. Ineligible controls 
were replaced, but no replacement was attempted for eligible control subjects who refused 
participation. Of 378 eligible cases and 372 controls, 369 cases (98%) and 320 controls 
(86%) provided questionnaire data and blood samples. A subset of samples was used for 
testing proteomics. 
4.2 STUDY DESIGN 
4.2.1 Nested Case-control Study in Sweden (Study I) 
To investigate whether early family structure, including maternal age, paternal age, number 
of siblings, number of older siblings, or number of younger siblings, is associated with the 
risks for NPC and IM, we have conducted two nested case-control studies, one for each 
health outcome.  
Regarding NPC, we included residents with available biological maternal information, alive 
and without a recorded diagnosis of NPC on January 1, 1961, or born after 1961 as our study 
population. We only focused residents born as singletons in Sweden in 1936 or later and up 
to 1992 [162]. Eligible NPC cases were those who were first diagnosed with NPC (ICD-7 
code: 146) between 1961 and 2009. Follow-up started on 1 January 1961 and was censored at 
the date of first NPC diagnosis, diagnosis of any other cancer, death, emigration out of 
Sweden or 31 December 2009, whichever occurred first.  
We identified 301 NPC cases during follow-up, of whom 251 aged ≥ 20 years at the date of 
diagnosis. We randomly selected 1255 control subjects (five controls per case) individually 
matched to NPC cases on year of birth and sex using a method of incidence density sampling 
[163]. Eligible controls were those who had not yet died, emigrated out of Sweden, or been 
diagnosed with any cancers at the identification of index case’s diagnosis.  
Regarding IM, we included individuals who were not diagnosed with IM (ICD-10: B27) 
before 2001 as our study population, because outpatient data are only available from 2001 
onward and most IM patients are not hospitalized. Eligible cases were those with a recorded 
diagnosis of IM between 2001 and 2009. Follow-up started on January 1, 2001, and was 
censored at the date of first diagnosis of IM, death, emigration out of Sweden, or December 
31, 2009, whichever occurred first. 
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We included 11,314 IM cases during follow-up. 56,570 control subjects (five controls per 
case) individually matched to IM case patients on year of birth and sex were randomly 
selected using incidence density sampling. 
4.2.2 Population Based Case-Control Study in Southern China (Studies II, III) 
Of 3027 histopathologically confirmed, first incident NPC cases identified from the study 
base in southern China, we have recruited a total of 2554 patients (84%). We have selected a 
total of 3202 controls; of these, 2648 (83%) agreed to participate the study. After excluding 
subjects with missing, ineligible, indeterminate, or poor-quality data, 2528 cases and 2596 
controls were analyzed in Study II, and 2499 cases and 2576 in Study III. 
We used data from questionnaire to retrieve self-reported oral health and hygiene information 
(Study II). Questions related to oral health condition included the number of teeth lost after 
age 20 years, age at first tooth lost after age 20 years, use of fixed dentures, number of teeth 
filled, daily frequency of brushing teeth, discomfort when eating particular foods, and food 
avoidance due to tooth or gum problems.  
Study III used family structure information from the questionnaire. Information on family 
included the number, sex, and age of parents, siblings and children, and cancer history in 
other relatives. For first-degree relatives, we then obtained information on cancer diagnosis 
regardless of their vital status at the time of interview. When a diagnosis of cancer had been 
reported in family members, we further obtained information including the type of cancer, 
age, hospital, diagnostic basis, and whether the diagnosis had been confirmed. If family 
members were deceased, we obtained information on reasons, years, and their ages at death. 
For second-degree relatives, we only obtained information on relatives who were diagnosed 
with cancers.  
Because information on first-degree family history of NPC was self-reported, information 
bias thus cannot be avoided. To check the magnitude of this bias, we used two approaches.  
First, we compared the NPC incidence rate of control families to that of the general 
population in the study area in 2011. Second, we validated information from all 41 NPC 
cases and 5 controls with a self-reported first-degree family history of NPC from Sihui 
County (where a population-based cancer registry is located), along with 52 randomly 
selected cases and 48 randomly selected controls (up to 5 subjects within each age stratum) 
who did not report a first-degree family history of NPC. We linked information on NPC 
diagnosis of the first-degree relatives (whose names and other identifying information were 
provided by relatives/local village doctors of cases and controls) from all 146 subjects to the 
Sihui Cancer Registry and/or medical records provided by village doctors. 
4.3 LABORATORY METHOD – AFFINITY ANTIBODY SUSPENSION BEAD 
ASSAYS (STUDY IV) 
Due to the sample availability, for Study IV, plasma samples from 174 cases and 175 
controls in Taiwan were used for proteomic testing. All samples were prepared according to 
standard procedures and stored at -80 °C until usage. We used two 384-well assay plates 
containing six 96-well microtiter plates for testing, and plate layout design is presented in 
Figure 9. The Taiwan samples were randomized across six different plates according to a 
plate layout that allowed an equal number of samples per plate and a balanced distribution of 
disease status (i.e. early stages, late stages, and healthy controls) and quality control samples 
across plates.  
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Figure 9 Plate layout design 
4.3.1 Antibodies and Bead Array Generation 
A total of 384 antibodies (including 2 positive controls and 2 negative controls) used in the 
present study were generated within the Human Protein Atlas project [164]. Protein selection 
was made based on prior knowledge of disease associations according to literature [165-180], 
and by including inflammatory markers and proteins expressed in possible tumorigenesis 
pathways [167, 181].  
As previously described [182], bead arrays were created by diluting 1.6 µg in 100 µL of 0.05 
M MES buffer (pH 4.5) prior to coupling to color-coded magnetic beads (MagPlex-C, 
Luminex) to create one 384plex bead array in suspension. The coupling of each antibody on 
the beads was confirmed via R-phycoerythrin-conjugated donkey anti-rabbit IgG antibody 
(Jackson ImmunoResearch), where all antibodies revealed median fluorescence intensity 
(MFI) values of 5 000−20 000 AU. 
4.3.2 Plasma Profiling 
Plasma samples stored at -80 °C were thawed at 4 °C, centrifuged for 10 min at 3000 rpm, 
and then transferred into 96-well microtiter plates. All samples were then diluted 1:10 in PBS 
and labeled with biotin, using liquid handling system (Selma, CyBio) as previously described 
[183]. The biotinylated samples were subsequently diluted 1:50 in an assay buffer composed 
of 0.5% (w/v) poly (vinyl alcohol) and 0.8% (w/v) polyvinylpyrrolidone (Sigma) in 0.1% 
casein in PBS (PVXC) supplemented with 0.5 mg/mL nonspecific rabbit IgG (Bethyl), 
yielding a total sample dilution of 1:500. Diluted samples were heat-treated for 30 min at 56 
°C and left to cool at room temperature for 15 min. Forty-five µL of heat-treated samples was 
then combined and added to 5 µL of the antibody suspension bead array in two 384-well 
microtiter plates (Greiner BioOne). The locations of the Taiwan samples were equally split 
across the two 384-well assay plates, resulting in a balanced number of samples and a similar 
distribution of disease subgroups across the two plates.  
The incubation took place overnight on a shaker (Grant) at room temperature and in the dark. 
Beads were washed with 3 × 60 µL PBS-T (1 × PBS pH 7.4, 0.05% Tween20) using a plate 
washer (EL406, Biotek) and incubated with 50 µL of 0.4% paraformaldehyde in PBS for 10 
min. Beads were then washed with 3 × 60 µL of PBS-T before adding 50 µL of 0.5 µg/mL R-
phycoerythrin labeled streptavidin (Invitrogen) in PBS-T and incubated for 20 min. Finally, 
beads were washed with 3 × 60 µL and measured in 60 µL PBS-T. Samples were measured 
in a FlexMap3D instrument (Luminex) were a minimum of 50 bead events per antibody were 
counted. MFI values were obtained for data analysis to allow relative measurement of 
proteins binding to the beads. 
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4.4 STATISTICAL METHODS  
4.4.1 Conditional Logistic Regression Model (Study I) 
In Study I, we used conditional logistic regression to estimate the ORs and corresponding 
95% CIs for risk of NPC or IM associated with early life exposure, conditioning on year of 
birth and sex. We included parental region of residence and parental occupation as the 
confounding factors. We tested for dose-response trends using an ordinal number of total 
siblings, older siblings, or younger siblings.  
In the NPC study, we conducted subgroup analyses by histopathological type. To reduce the 
selection bias caused by the incompleteness of Multi-Generation Register data for residents 
who were born before 1932 or who died between 1968 and 1990, we also conducted 
sensitivity analyses by limiting subjects who born in 1941 or later, or by restricting to cases 
diagnosed with NPC in 1991 or later and their respective matched controls,  
4.4.2 Unconditional Logistic Regression Model (Studies II, III, IV) 
The associations between oral health indicators (Study II), a family history of NPC (Study 
III), and NPC risk were estimated by ORs and the corresponding 95% CIs derived from 
multivariate unconditional logistic regression models. Frequency-matching variables of age 
(in 5-year groups), sex, and residential area (Zhaoqing, Wuhzou or Guiping/Pingnan) were 
included in minimally-adjusted multivariable model.  
We used a two-step approach to determine variables in the fully-adjusted multivariable 
model. In addition to frequency-matching variables, covariates were firstly considered based 
on prior knowledge and others were considered if they changed the minimally-adjusted OR 
of NPC for exposures by more than 10%. We then utilized forward stepwise confounder 
selection, in which the effect of adding one confounder at a time was evaluated. 
In Study II, to control for residual confounding effect caused by smoking, we conducted a 
subgroup analysis which was restrict to non-tobacco users. We tested for linear trends with 
ordinal variables in the models, using the median value within each category. Likelihood ratio 
tests for interaction terms were used to compare logistic regression models with and without 
an interaction term between oral health indicators and each potential effect modifier.  
In Study III, unconditional logistic regression models were used to estimate the associations 
between a positive family history of NPC or other cancers, overall and for specific relatives. 
To evaluate potential influence of reporting bias, using information on sensitivity and 
specificity of self-reported first-degree family history of NPC among cases and controls 
obtained from a validation study, we conducted a sensitivity analysis to estimate the OR 
adjusted for this bias. The population attributable risk for first-degree family history of NPC 
adjusted for potential confounding factors was also estimated [184].  
In Study IV, unconditional logistic regression models were used to estimate the ORs (third 
quartile vs. lowest quartile) and 95% CI to examine the difference of individual biomarker 
between NPC cases in early stages and healthy controls. All models were adjusted for age 
and sex and controlled for a false discovery rate (FDR) at 5% to obtain the corrected P 
values. 
4.4.3 Cox Proportional Hazards Regression Model (Study III) 
In Study III, in addition to aforementioned logistic regression model, we used Cox 
proportional hazards regression models, to estimate hazard ratios (HRs) with 95% CIs in 
association with a positive family history of NPC among first-degree relatives, adjusting for 
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age (as the time scale), sex, and geographic area, and stratifying baseline hazards by familial 
relationship. Different from traditional case-control study design using logistic regression 
model to estimate the OR as the relative risk, this method can help us to fully account for the 
family size and structure of each respondent, and the affected relative’s age at onset. We 
firstly attempted to reconstruct a kin cohort, using family structure information reported by 
the index person. From 42,024 first-degree relatives, we excluded 1243 with an unknown age 
at death or cancer diagnosis; leaving 40,781 relatives in the cohort analysis. To avoid the 
influence of familial aggregation, a method described by Lee was used to account for the 
intracluster dependence [185]. We also estimated the nonproportionality of hazards [186] and 
no violations were observed.   
4.4.4 Cumulative Risk Estimates (Study III) 
We used two approaches to calculate the absolute risk (i.e. cumulative risk) for individuals 
with a positive family history of NPC. First, because of the population-based design and the 
relative low incidence of NPC, i.e. the OR is a good estimate of relative risk, we were able to 
quantify cumulative risks of NPC for the first-degree relatives, by multiplying their age-
specific OR estimates by the age-specific NPC cumulative risks in the underlying population 
in 2011. Second, to further account for the family size and structure of each index person, 
Kaplan-Meier method was used to derive the cumulative risk of NPC. Disease-specific 
survival curves were plotted. Follow-up duration of all first-degree relatives was considered 
from birth until his/her age at the date of interview, age at death, age at diagnosis of NPC or 
cancers other than NPC, whichever occurred first.  
4.4.5 Marker Selection and Diagnostic Performance (Study IV) 
We used two approaches to conduct the quality control and normalization. First, we detected 
sample outliers by robust principal component analysis by using the “rrcov” R package [187]. 
In the present study, no sample was removed based on the graphic diagnostics. Second, we 
compared median values of intraclass correlation coefficient (ICC) from six schemes using 
two normalization approaches and found that the data which subjected to probabilistic 
quotient normalization (PQN, to consider within-plate variation) [188] and unsmoothed 
multi-normalization (MA, to consider across-plate variation (PQN-MA-Ind) [189]. 
After data processing, the comparisons were made with a focus on NPC cases in early stages 
and controls, and the receiver operating characteristic (ROC) curves were constructed using 
different combinations of sensitivity and specificity. The areas under the curves (AUCs) and 
with corresponding 95% CIs were calculated for the selected biomarkers. We also calculated 
sensitivity, specificity, PPV, and negative predictive value (NPV), and their corresponding 
95% CIs, by using the optimal values determined from the ROC curves as the cutoffs. 
Finally, we calculated AUC and 95% CI according to a multivariable logistic regression 
models including all selected biomarkers.  
Data were analyzed using R version 3.1.2 (http://www.R-project.org/), SAS version 9.4 (SAS 
Institute, Cary, NC), and Stata version 13.1 (Stata Corporation, College Station, TX). 
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5 RESULTS 
5.1 STUDY I 
Males were more likely to develop both NPC and IM than females in Sweden. The median 
age at NPC diagnosis was higher than that at IM diagnosis (49 years vs. 18 years). The 
associations between early-life family structure and risk of NPC and that of IM had different 
patterns (Table 1). We observed an increased NPC risk with an increasing number of 
siblings. Compared with those who did not have any siblings, those with three or more 
siblings had an adjusted OR of 2.03 (95% CI = 1.23, 3.35, Ptrend = 0.006). Exposure to older 
siblings was more likely to contribute to an increased risk of NPC, as suggested by a 
significant dose-response trend with an increasing number of older siblings (Ptrend= 0.019) but 
no such trend was observed with an increasing number of younger siblings (Ptrend= 0.166). 
For IM, in contrast, we found an inverse association for IM risk associated with an increasing 
number of siblings (Ptrend < 0.001), older siblings (Ptrend < 0.001), and younger siblings (Ptrend 
< 0.001).   
Table 1. Odds ratios (ORs) and their 95% confidence intervals (CIs) for nasopharyngeal 
carcinoma and infectious mononucleosis according to familial characteristics in two nested case-
control studies in Sweden. * 
Variables 
Nasopharyngeal carcinoma Infectious mononucleosis 
Cases 
(n=251) 
Controls  
(n=1,255) OR (95% CI)  
Cases  
(n=11,314) 
Controls  
(n=56,570) OR (95% CI) 
% % % % 
Sibship size       
  0 9.5 16.1 referent 7.6 6.7 referent 
  1 29.9 32.0 1.59 (0.97, 2.62) 46.4 42.1 0.96 (0.88, 1.04) 
  2 28.3 25.0 1.94 (1.17, 3.22) 32.0 33.8 0.82 (0.76, 0.89) 
  ≥ 3 32.3 26.9 2.03 (1.23, 3.35) 14.0 17.4 0.72 (0.65, 0.79) 
Ptrend   0.006   < 0.001 
No. of older siblings      
  0 42.6 48.8 referent 41.1 42.1 referent 
  1 35.5 30.8 1.54 (1.11, 2.14) 37.7 36.0 0.91 (0.87, 0.96) 
  2 14.7 13.0 1.65 (1.06, 2.57) 15.9 15.8 0.84 (0.78, 0.89) 
  ≥ 3 7.2 7.3 1.50 (0.83, 2.71) 5.2 6.1 0.73 (0.66, 0.81) 
Ptrend   0.019   < 0.001 
No. of younger siblings     
  0 36.7 41.9 referent 48.6 43.3 referent 
  1 31.9 31.9 1.15 (0.81, 1.63) 35.9 37.3 0.83 (0.78, 0.87) 
  2 15.9 16.3 1.03 (0.67, 1.58) 12.4 14.8 0.73 (0.68, 0.79) 
  ≥ 3 15.5 10.8 1.51 (0.95, 2.40) 3.1 4.6 0.63 (0.56, 0.71) 
Ptrend   0.166   < 0.001 
* ORs and 95% CIs were conditioned on matching variables (year of birth and sex), and further 
adjusted for parents’ region of residence, parents’ occupation, and other factors listed in the table 
except for sibship size. 
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We found null associations between maternal or paternal age and NPC risk, and between 
paternal age and risk of IM. On the other hand, an increased risk for IM was associated with 
an increased maternal age. Stratified analyses by histopathological types showed that the ORs 
for those with one or more siblings increased among squamous cell carcinoma and 
undifferentiated carcinoma, compared with those having no siblings (Table 2), although the 
associations were slightly stronger for the latter. No such association was observed for other 
or unclassified NPC. The associations estimated from two sensitivity analyses did not change 
substantially.   
Table 2. Odds ratios (ORs) and their 95% confidence intervals (CIs) for nasopharyngeal 
carcinoma by histopathological type in a nested case-control study in Sweden. * 
Sibship 
size 
Squamous cell carcinoma  Undifferentiated carcinoma  Other or unclassified 
OR (95% CI)   OR (95% CI)   OR (95% CI)  
  0 referent  referent  referent 
  1 1.99 (0.96, 4.14)  1.71 (0.51, 5.75)    1.20 (0.51, 2.82) 
  2 1.93 (0.90, 4.12)  2.74 (0.84, 8.98)    1.79 (0.76, 4.24) 
  ≥ 3 2.15 (1.04, 4.46)    3.24 (0.99, 10.62)    1.33 (0.53, 3.29)   
Ptrend 0.106  0.021  0.374 
* ORs and 95% CIs for nasopharyngeal carcinoma were conditioned on matching variables (year of 
birth and sex), and further adjusted for parents’ region of residence, parents’ occupation, maternal 
age, and paternal age. 
5.2 STUDY II 
Baseline characteristics of the study population are shown in Table 3. The distributions of 
residential areas and sex were similar among cases and controls, whereas cases were slightly 
younger than controls at enrollment, and were more likely to be less educated, live in 
cottages, have blue-collar jobs, have a first-degree family history of NPC, have ever smoked, 
and have consumed salt-preserved fish at least weekly in 2000-2002.  
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Table 3. Characteristics of nasopharyngeal carcinoma (NPC) cases and controls 
Characteristics 
Cases (n=2528)   Controls (n=2596) 
P value * 
No.  %   No.  % 
Residential area 
     
0.28 
    Zhaoqing 1283 50.8 
 
1321 50.9 
 
    Wuzhou 688 27.2 
 
664 25.6 
 
    Guiping/Pingnan 557 22.0 
 
611 23.5 
 
Sex 
     
1.00 
    Male 1858 73.5  1908 73.5  
    Female 670 26.5  688 26.5  
Age at diagnosis/referral (years)        
    20-29 82 3.3  80 3.1 0.007 
    30-39 423 16.7  372 14.3  
    40-49 910 36.0  890 34.3  
    50-59 686 27.1  729 28.1  
    60-74 427 16.9  525 20.2  
Education level (years)      0.003 
    ≤ 6  1005 39.8  932 35.9  
    7- 9 1013 40.1  1040 40.1  
    10-12 403 15.9  483 18.6  
     > 12 107 4.2  141 5.4  
Current housing type    
 
 <0.001 
   Building (concrete structure) 1818 71.9  2019 77.8  
   Cottage (clay brick structure) 700 27.7  574 22.1  
   Boat 10 0.4 
 
2 0.1  
Current occupation  
     
<0.001 
   Unemployed 77 3.1  95 3.7  
   Farmer 855 33.8  984 37.9  
   Blue-collar 1020 40.4  900 34.7  
   White-collar 350 13.8  416 16.0  
   Other/unknown 226 8.9 
 
201 7.7  
First-degree family history of NPC  
     
<0.001 
   No 2204 87.2  2482 95.6  
   Yes 272 10.8  70 2.7  
   Unknown 46 1.8  43 1.7  
Cigarette smoking  
    
 0.07 
    Never 1117 44.2 
 
1213 46.7  
    Ever 1410 55.8 
 
1381 53.2  
Tea drinking 
     
<0.001 
    Less than daily 1614 63.8 
 
1512 58.2  
    Daily 911 36.1 
 
1081 41.6  
Salt-preserved fish consumption in 
2000-2002 
     
0.02 
   Yearly or less 1853 73.3 
 
1901 73.2 
    Monthly 484 19.2 
 
542 20.9 
    Weekly or more 188 7.4 
 
149 5.7 
 *P value was determined by a two-sided t-test. Other P values were determined by a chi-square test. 
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The adjusted ORs for the associations of oral health indicators with NPC risk are shown in 
Table 4. Increased number of teeth lost after age 20 was not associated with a higher risk of 
NPC in either minimally adjusted models (Ptrend = 0.46) or fully adjusted models (Ptrend = 
0.98). Nevertheless, among those who had experienced tooth loss, we found a marginal 
association between earlier age at first tooth loss with an increasing risk of NPC (Ptrend = 
0.08). The fully-adjusted ORs (95% CIs) for those with first tooth loss at 40-49, 30-39, and 
20-29 vs. ≥ 50 years were 1.18 (0.91, 1.53), 1.23 (0.93, 1.62), and 1.33 (0.98, 1.79), 
respectively. Increasing risks of NPC with an increasing number of teeth filled were also 
observed in both minimally adjusted model (Ptrend = 0.003) and fully adjusted model (Ptrend = 
0.002). For example, compared with those who had not had any teeth filled, those with 1 to 3 
or more than 3 teeth filled had significantly increased risks of NPC, with ORs of 1.25 (95% 
CI = 1.06, 1.49) and 1.55 (95% CI = 1.13, 2.12), respectively. In contrast, more frequent 
tooth brushing was inversely associated with the risk of NPC. Compared with less frequent 
brushing, brushing teeth twice per day or more had a fully adjusted OR of 0.62 (95% CI = 
0.55, 0.70). Further adjustment for alcohol intake, a self-reported history of chronic rhinitis, 
herbal medicine intake, and intake of green leafy vegetables (g/day) and fruits (g/day) in 
2000-2002 or detailed smoking history (i.e. never, former, or current plus pack-years) did not 
significantly change the magnitude of the associations (data not shown).  
Among never smokers, the strength of the associations with oral health variables was similar 
to that in the overall study population, except that earlier age at first tooth loss was not 
associated with a higher risk of NPC (data not shown).  
We selected number of teeth lost after age 20 and frequency of tooth brushing as the two 
main oral health indicators and tried to test the heterogeneity in the associations by sex, age 
group, education level, first-degree family history of NPC, or salt-preserved fish 
consumption. No significant heterogeneity was detected (data not shown).  
We did not detect any appreciable changes in the magnitude of associations from two 
sensitivity analyses, one excluding the 32 replacement controls in Wuzhou who participated 
in a screening program for NPC, and one limiting to cases interviewed within 30 days of 
diagnosis (2166 cases, 86% of 2528, data not shown). 
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Table 4. Odds ratios (ORs) and 95% confidence intervals (CIs) of nasopharyngeal carcinoma 
associated with oral health in southern China (2010-2014). 
Variable Cases (n=2528)   
Controls 
(n=2596) 
Minimally 
adjusted OR Fully adjusted OR 
No.  %   No.  %  (95% CI) *  (95% CI) †  
Number of teeth lost after 
age 20 years 
        None 1282 50.7  1268 48.8 referent referent 
  1 - 3 701 27.7  739 28.5 0.98 (0.86, 1.12)  0.97 (0.84, 1.11)  
  4 - 13 417 16.5  453 17.5 1.01 (0.85, 1.19)  0.99 (0.83, 1.18)  
   ≥ 14 128 5.1  136 5.2 1.10 (0.84, 1.45)  1.00 (0.75, 1.32) 
P for trend      0.46 0.98 
Age at first tooth loss 
(years) ‡       
    ≥ 50 202 16.2  306 23.0 referent referent 
   40 - 49 285 22.9  352 26.5  1.12 (0.87, 1.44)  1.18 (0.91, 1.53) 
   30 - 39 304 24.4  323 24.3  1.26 (0.96, 1.64)   1.23 (0.93, 1.62)  
   20 - 29 297 23.8  289 21.8  1.34 (1.00, 1.79)   1.33 (0.98, 1.79)  
   unknown 158 12.7  58 4.4 - - 
P for trend      0.04 0.08 
Number of filled 
teeth        
  None 2077 82.2  2223 85.6 referent referent 
  1 - 3 352 13.9  297 11.4 1.25 (1.06, 1.47)  1.25 (1.06, 1.49)  
  ≥ 4 99 3.9  76 2.9 1.39 (1.03, 1.89)  1.55 (1.13, 2.12)  
P for trend      0.003 0.002 
Frequency of brushing 
teeth (times/day)       
  ≤ 1 1696 67.1  1456 56.1 referent referent 
  ≥ 2 824 32.6  1133 43.6 0.58 (0.52, 0.66)  0.62 (0.55, 0.70)  
  Irregular 8 0.3  7 0.3 - - 
* Adjusted for sex, age (5-year categories), and residential area (Zhaoqing, Wuzhou, or 
Guiping/Pingnan). 
† Adjusted for sex, age, residential area, education level (≤ 6, 7-9, 10-12, or >12 years), current 
housing type (building, cottage, or boat), current occupation (unemployed, farmer, blue-collar, 
white-collar, or other/unknown), first-degree family history of nasopharyngeal carcinoma (yes, no, 
or unknown), cigarette smoking (ever or never), tea drinking (less than daily or daily), and salt-
preserved fish consumption in 2000-2002 (yearly or less, monthly, or weekly or more). We 
excluded 18 subjects due to missing covariate values. 
‡ Among 2574 participants who experienced tooth loss after age 20 years. 
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5.3 STUDY III 
Cases and controls had similar numbers of first-degree relatives (median 8 vs 8), number of 
siblings (median 4 vs 4), and number of offspring (median 2 vs 2) (Table 5). The sibling sex 
distribution was similar between cases and controls, but siblings of controls were on average 
older than those of cases. The median number of offspring and their age and sex distribution 
were similar between cases and controls, except that sons of controls were slightly older than 
those of cases. 
Table 5. Distribution of family size, number and age of siblings, and number and age 
of offspring in nasopharyngeal carcinoma cases and controls. 
  Cases (No=2499) Controls (No=2576) 
Family size, median (range) * 8 (2-18) 8 (2-18) 
Siblings 
      No. of siblings, median (range) 4 (0-11) 4 (0-13) 
    No. of brothers (% siblings) 4749 (51%) 4625 (50%) 
    Mean age of brothers (years) † 47.8 49.0 
    No. of sisters (% siblings) 4566 (49%) 4703 (50%) 
    Mean age of sisters (years) † 48.1 49.0 
Offspring   
    No. of offspring, median (range) 2 (0-11) 2 (0-8) 
    No. of sons (% offspring) 3487 (54%) 3671 (55%) 
    Mean age of sons † 22.3 23.5 
    No. of daughters (% offspring) 3015 (46%) 3058 (45%) 
    Mean age of daughters † 23.3 23.6 
* Family size includes all first-degree relatives except the index person. 
† Age at the date of interview of the index person. For relatives who died before the 
interview, age at death was used. 
 
Relative risk estimates associated with a positive family history of NPC 
We found that people with a first-degree family history of NPC were at a higher risk for 
NPC, compared to those without, but had no excess risk of other malignancies. Overall, 
10.8% of cases had reported a positive family history of NPC among first-degree relatives, 
versus 2.7% of controls (Table 6). Associations were similar between models minimally 
adjusted for sex, age, residential area, and family size and models fully adjusted for these four 
variables plus education level, current housing type, current occupation, cigarette smoking, 
tea drinking, and salt-preserved fish consumption in 2000-2002. The fully-adjusted ORs of 
NPC associated with ever having any NPC diagnosis among first-degree relatives was 4.6 
(95% CI = 3.5, 6.1).  NPC risk increased for those with a greater number of affected relatives; 
the fully adjusted ORs (95% CIs) for having one or at least two affected relatives were 4.4 
(3.3, 5.9) and 6.7 (2.8, 16.0), respectively (Ptrend < 0.001). The strength of the association was 
greater for having a mother (OR=5.6) than a father (OR=3.1) with NPC, and slightly but not 
significantly greater for having an affected sibling (OR=5.1) than a parent (OR=4.0), and a 
sister (OR=5.6) than a brother (OR=4.8). A history of NPC in offspring was not associated 
with a significantly higher risk of NPC (OR=1.6, 95% CI = 0.3, 10.0); however, because of 
the relative young age (22-24 years) of the offspring of cases and controls, the number of 
affected offspring was very small.  
  27 
Table 6. Odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) for risk 
of nasopharyngeal carcinoma (NPC) in association with family history of NPC in first-
degree relatives. 
  Cases Controls Minimally adjusted OR (95% CIs) *  
Fully adjusted OR 
(95% CIs) † (n=2499) (n=2576) 
Family history of 
NPC in first-degree 
relatives     
No 2208 2483 referent referent 
Yes 270 69 4.5 (3.4, 5.8)  4.6 (3.5, 6.1)  
      1 affected 236 63 4.3 (3.2, 5.7)  4.4 (3.3, 5.9)  
      ≥2 affected 34 6 6.6 (2.7, 15.7)  6.7 (2.8, 16.0)  
P for trend   <0.001 <0.001 
Affected relatives ‡     
Father     
   No 2421 2543 referent referent 
   Yes 72 26 2.9 (1.8, 4.5) 3.1 (2.0, 5.0) 
Mother     
   No 2429 2561 referent referent 
   Yes 58 11 5.4 (2.8, 10.4) 5.6 (2.9, 10.8) 
Parent     
   No 2357 2529 referent referent 
   Yes 130 37 3.7 (2.6, 5.4) 4.0 (2.7, 5.8) 
Brother     
   No 2332 2478 referent referent 
   Yes 113 26 4.7 (3.0, 7.2) 4.8 (3.1, 7.4) 
Sister     
   No 2395 2499 referent referent 
   Yes 53 10 5.7 (2.9, 11.3) 5.6 (2.8, 11.1) 
Siblings     
   No 2283 2466 referent referent 
   Yes 159 35 5.0 (3.5, 7.3) 5.1 (3.5, 7.4) 
     1 affected 142 34 4.6 (3.2, 6.8) 4.7 (3.2, 6.9) 
      ≥2 affected 17 1 19.1 (2.5, 144.1) 18.9 (2.5, 142.8) 
P for trend   <0.001 <0.001 
Offspring      
   No 2355 2436 referent referent 
   Yes 3 2 1.7 (0.3, 10.4)  1.6 (0.3, 9.9)  
* Adjusted for age, sex, residential area, and family size (continuous; see below). 
†Adjusted for age, sex, residential area, family size (see below), education level, current housing 
type, current occupation, cigarette smoking, tea drinking, and salt-preserved fish consumption in 
2000-2002.  
‡ In analyses of history of NPC in parents, fathers, or mothers, ORs were not adjusted for family 
size. In analyses of history of NPC in brothers or sisters, siblings, or offspring, ORs were adjusted 
for number of brothers, number of sisters, number of siblings, or number of offspring, 
respectively.  
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A self-reported second-degree family history of NPC was also associated with a higher risk 
of NPC (OR = 5.3, 95% CI = 3.4, 8.3), and the excess risks increased with a greater number 
of affected second-degree relatives (P trend < 0.001).  
Based on the fully adjusted OR, up to 8.6% (95% CI = 5.9%, 11.3%) of all incident NPC 
cases in the population are attributable to a first-degree family history of NPC. 
We identified a total of 20,157 first-degree relatives of cases and 20,624 first-degree relatives 
of controls. The overall adjusted HR for NPC in first-degree relatives of cases compared with 
controls was 4.2 (95% CI = 3.2, 5.5). As shown in Figure 10, the HR was higher for those 
with an affected sibling than an affected parent, and it was also slightly higher for those with 
an affected mother versus a father, and for those with an affected sister versus a brother. 
 
Figure 10 Hazard ratios and 95% confidence intervals for nasopharyngeal carcinoma 
by relationship of the affected relatives. 
Cumulative risk of NPC associated with a positive family history of NPC 
The estimated cumulative risks of NPC for people with a positive first-degree family history 
of NPC are listed in Table 7. Because only one sister aged <50 years affected with NPC was 
reported among male controls and only one mother affected with NPC was reported among 
female controls, the cumulative risks in these groups were not estimated. We found that 
between ages 20 and 74, the cumulative risk of NPC for males with any affected first-degree 
relative was 5.0% (95% CI = 3.6%, 7.0%), ranging from 4.2% with an affected father to 6.3% 
with an affected sister. For females, between ages 20 and 74, the cumulative risk of NPC with 
any affected first-degree relative was 1.9% (95% CI = 1.1%, 3.2%), ranging from 0.8% with 
an affected father to 2.2% with an affected brother.  
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Table 7. Adjusted odds ratios (ORs) and estimated cumulative risks (%), with corresponding 95% confidence intervals, of nasopharyngeal carcinoma 
(NPC) by type of relatives affected with NPC and by age (years) and sex of subjects * 
  
Males   Females 
- 50 years - 60 years  - 74 years    - 50 years - 60 years  - 74 years 
General population (2011, %) 0.4 0.7 1.1  0.2 0.3 0.4 
Any first-degree relatives        
   Adjusted OR 5.7 (3.5, 9.3) 5.3 (3.7, 7.7) 4.7 (3.4, 6.5)  4.3 (2.0, 8.9) 4.5 (2.5, 8.3) 4.6 (2.7, 7.8) 
   Cumulative risk (%) 2.2 (1.4, 3.6) 3.9 (2.7, 5.7) 5.0 (3.6, 7.0)  0.7 (0.3, 1.5) 1.3 (0.7, 2.4) 1.9 (1.1, 3.2) 
Father        
   Adjusted OR 3.7 (1.7, 7.8) 4.5 (2.4, 8.6) 3.9 (2.2, 6.8)  2.0 (0.7, 5.6) 1.8 (0.7, 4.4) 1.9 (0.8, 4.3) 
   Cumulative risk (%) 1.4 (0.7, 3.0) 3.3 (1.8, 6.4) 4.2 (2.4, 7.3)  0.3 (1.2, 9.5) 0.5 (0.2, 1.3) 0.8 (0.3, 1.8) 
Mother †        
   Adjusted OR 6.1 (2.4, 15.9) 4.5 (2.2, 9.3) 4.4 (2.2, 8.9)  N/A N/A N/A 
   Cumulative risk (%) 2.4 (0.9, 6.2) 3.3 (1.6, 6.9) 4.7 (2.4, 9.5)  N/A N/A N/A 
Brother        
   Adjusted OR 5.2 (2.0, 13.7) 5.2 (2.7, 9.7) 4.6 (2.8, 7.6)  4.0 (1.0, 15.5) 4.2 (1.6, 10.9) 5.4 (2.3, 12.8) 
   Cumulative risk (%) 2.0 (0.8, 5.3) 3.9 (2.0, 7.2) 4.9 (3.0, 8.1)  0.7 (0.2, 2.6) 1.2 (0.5, 3.2) 2.2 (0.9, 5.3) 
Sister ‡        
   Adjusted OR N/A 6.5 (2.5, 16.9) 5.9 (2.6, 13.2)  3.1 (0.6, 15.9) 5.8 (1.3, 26.5) 4.4 (1.2, 15.7) 
   Cumulative risk (%) N/A 4.8 (1.9, 12.5) 6.3 (2.8, 14.1)  0.5 (0.1, 2.7) 1.7 (0.4, 7.7) 1.8 (0.5, 6.4) 
*Adjusted for age, residential area, family size (see below), education level, current housing type, current occupation, cigarette smoking, tea drinking, and salt-
preserved fish consumption in 2000-2002.  
In analyses of history NPC in fathers, or mothers, ORs were not adjusted for family size. In analyses of history NPC in brothers or sisters, ORs were adjusted for 
number of brothers or number of sisters, respectively.  
† Only one mother affected with NPC was reported among female controls; therefore, the cumulative risk was not estimated. 
‡ Only one sister aged <50 years affected with NPC was reported among male controls; therefore, the cumulative risk in this age group was not estimated 
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Based on the reconstructed kin cohort, we were able to estimate the lifetime cumulative risks 
of NPC up to age 74 years among first-degree relatives of cases and controls and results are 
shown in Table 8. The cumulative risk of NPC among relatives of cases was higher than that 
of controls (3.7% vs. 0.9%). The incidence rate ratio comparing age-specific risk of NPC in 
relatives of cases vs. controls was as high as 12.4 at ages up to 29 years, and gradually 
decreased with advancing age to 3.7 at ages up to 74 years. 
Table 8. Lifetime cumulative risks (%) and incidence rate ratios, with corresponding 95% confidence 
intervals (CIs), of nasopharyngeal carcinoma (NPC) among first-degree relatives of cases and 
controls, by age of relatives 
 
Age of first-degree relatives (years) 
 - 29  - 39  - 49   - 59  - 74 
Controls 
        No. of relatives at risk 20,624 15,522 12,542 8,712 5,678 
   Cumulative No. of NPCs 1 11 42 62 74 
   Cumulative risk (%) 0.006 0.1 0.4 0.6 0.9 
   95% CIs 0.001, 0.04 0.08, 0.2 0.3, 0.5 0.5, 0.8 0.7, 1.2 
Cases      
   No. of relatives at risk 20,157 14,871 11,838 7,994 5,278 
   Cumulative No. of NPCs 13 68 168 250 291 
   Cumulative risk (%) 0.08 0.5 1.5 2.7 3.7 
   95% CIs 0.05, 0.1 0.4, 0.6 1.3, 1.7 2.4, 3.0 3.3, 4.2 
Cases versus controls      
   Incidence rate ratio 12.4 5.4 3.2 4.6 3.7 
   95% CIs 1.9, 526.4 2.7, 11.8 2.1, 5.0 2.8, 7.9 1.9, 7.7 
 
Figure 11 shows the relative-specific cumulative risks of NPC up to age 74 years. We found 
that lifetime cumulative risk up to age 74 years of NPC was greater in siblings of NPC cases 
(6.3% in brothers, 3.5% in sisters), than in parents (3.4% in fathers, and 2.5% in mothers). In 
contrast, there were no differences in cumulative risks of NPC between siblings of and 
parents of population-based controls. For male relatives, brothers had a higher cumulative 
risk of NPC that fathers of cases, but no such difference was observed among brothers and 
fathers of controls. No significant differences were found between mothers and sisters of 
cases or controls (data not shown). 
Validation on family history of NPC 
We confirmed a positive first-degree family history of NPC according to cancer registry data 
and/or medical records among 39 of 41 cases and 5 of 5 controls, and for a negative family 
history for 50 of 52 cases and 45 of 48 controls in Sihui City. The reasons for a lack of 
confirmation were incorrect contact information (N=3) and inability to recall the names of 
first-degree relatives (N=4). Among cases, the sensitivity and specificity for self-reported 
first-degree family history of NPC were 95% (95% CI = 88%, 100%) and 98% (95% CI = 
94%, 100%), respectively; among controls, they were 83% (95% CI = 54%, 100%) and 100% 
(95% CI = 100%, 100%), respectively. Among cases, the positive predictive value and 
negative predictive value for self-reported first-degree family history of NPC were 97% and 
96%, respectively; among controls, they were 100% and 98%, respectively. The number of 
observed (self-reported) NPC cases between ages 20 and 74 among first-degree relatives of 
controls was slightly higher than that expected in the general population of the overall study 
area in 2011 (74 observed vs. 59 expected among controls, standardized incidence ratio=1.2, 
P=0.07). After correcting for misclassification, the OR associated with having at least one 
affected first-degree relative was 3.1. 
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Figure 11 Cumulative incidence of nasopharyngeal carcinoma (NPC) among different 
relatives of NPC cases and controls.  
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5.4 STUDY IV 
We utilized plasma samples from 174 NPC cases and 175 community-based controls 
collected in Taiwan. Number of bead counts across all 384 biomarkers (including 2 positive 
controls and 2 negative controls) are acceptable. We found that PQN-MA-Ind had the highest 
median ICC across all biomarkers of 0.81, compared with other 5 normalization schemes 
(Figure 12), thus we used PQN-MA-Ind as our normalization method.  
 
Figure 12 Density plot of ICC distributions and scatter plot and correlation between 
unsmoothed multi-dimensional normalization after probabilistic quotient normalization 
(PQN-MA-Ind) and smoothed multi-dimensional normalization after probabilistic 
quotient normalization (PQN-MA-loess) 
Results from unconditional logistic regression models, adjusted for age and sex, showed that 
nine biomarkers had significant P values after controlling false discovery rate at 5%. One 
biomarker, interleukin 6 receptor (IL6R) was excluded because of a low ICC of 0.28, leaving 
eight biomarkers in the panel. They are cyclin B1 (CCNB1), kinase insert domain receptor 
(KDR, also known as vascular endothelial growth factor receptor 2 [VEGFR2]), hyaluronan 
synthase 1(HAS1), lymphocyte antigen 6 complex locus K (LY6K), interleukin 2 receptor 
subunit alpha (IL2RA), chemokine (C-X-C motif) ligand 10 (CXCL10), platelet-derived 
growth factor beta polypeptide (PDGFB), and lectin galactoside-binding soluble 1(LGALS1). 
Table 9 shows the individual performance of eight selected biomarkers for early detection of 
NPC. A combination of these eight biomarkers showed a high accuracy to distinguish NPC 
patients in early stages from controls (AUC = 0.808, 95% CI: 0.745, 0.871) (Figure 13). 
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Table 9. Performance of eight selected biomarkers for early detection of nasopharyngeal carcinoma. 
Gene name Sensitivity  (95% CI) 
Specificity 
(95% CI) 
PPV  
(95% CI) 
NPV  
(95% CI) 
AUC  
(95% CI) 
CCNB1  42.4 (30.3, 55.2) 80.6 (73.9, 86.1) 45.2 (36.0, 57.9) 78.8 (68.9, 84.8)  0.651 (0.572, 0.729)  
KDR 
(VEGFR2) 69.7 (57.1, 68.9) 61.7 (54.1, 68.9) 40.7 (33.4, 55.1) 84.4 (75.8, 88.1) 0.667 (0.594, 0.740) 
PDGFB   69.7 (62.3, 76.4) 65.1 (52.4, 76.5) 84.1 (75.8, 88.2) 44.8 (36.8, 58.1) 0.682 (0.607, 0.757) 
LGALS1 60.6 (52.9, 67.8) 66.7 (54.0, 77.8) 82.8 (73.9, 86.9) 38.9 (31.8, 52.8) 0.661 (0.586, 0.736) 
HAS1  54.5 (41.8, 66.9) 73.7 (66.5, 80.1) 43.9 (35.7, 56.8) 81.1 (72.0, 86.0)  0.630 (0.545, 0.715)  
LY6K  78.8 (67.0, 88.9) 45.7 (38.2, 53.4) 35.4 (28.6, 51.7) 85.1 (75.7, 88.6) 0.639 (0.563, 0.716) 
IL2RA 71.2 (58.7, 81.7) 56.0 (48.3, 63.5) 37.9 (31.0, 52.4) 83.8 (74.8, 87.6) 0.646 (0.568, 0.724) 
CXCL10 48.5 (36.0, 61.1) 77.1 (70.2, 83.1) 44.4 (35.8, 57.2) 80.0 (70.3, 85.3) 0.640 (0.558, 0.723) 
Abbreviations: CI, confidence interval, PPV, positive predictive value; NPV, negative predictive value; AUC, area 
under the receiver operating characteristic curve 
 
Figure 13 Performance to detect nasopharyngeal carcinoma in early stages. The 
receiver operating characteristic (ROC) curve from a combination of eight selected 
biomarkers established from an unconditional logistic regression model.   
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6 DISCUSSSION 
6.1 FINDINGS AND IMPLICATIONS 
The results of this thesis indicate that NPC risk is highly related to the early-life social 
environment, especially for that associated with EBV infection, as further supported by the 
clearly contrasting findings between NPC and IM in a non-endemic area. In endemic areas, 
poor oral hygiene indicators were associated with a higher risk of NPC and improvement of 
oral hygiene might contribute to a lower NPC risk. The excess risk of a positive family 
history of NPC is higher for a maternal than a paternal history and slightly stronger for a 
sibling than a parental history, and for a sororal than a fraternal history. Such evidence 
highlights the need of strategic development for early detection and clinical consultation in 
NPC high-incidence populations. By applying antibody suspension bead array assays, we 
have identified eight proteins, which might be a potential panel to facilitate early detection of 
NPC. 
6.1.1 NPC Risk Assessment   
Early-Life Risk Factors 
So far, most of our knowledge related to risk factors for NPC has been obtained from studies 
on populations at a high- to intermediate-incidence, studies on low-incidence areas are 
required to understand the complexity of NPC etiology between endemic and non-endemic 
areas [17, 190], and between type I and type II/III NPC. In low-incidence areas, however, due 
to the fact that NPC is an extremely rare disease, it is difficult to achieve enough statistical 
power to address research questions in terms of risk assessment. The Swedish population 
registers have provided us valuable resources. We had originally hypothesized that early-life 
infection with EBV contributes to the pathogenesis of NPC and thus may be associated with 
the subsequent NPC risk later in life. Although a history of IM, which is caused by delayed 
infection with EBV, has been proposed to entail a lower risk of NPC, most of the previous 
studies are based on few cases with such a history [7, 45, 46]. In high-incidence areas, most 
of individuals are infected with EBV in an early age, precluding us to investigate such 
association. We therefore utilized early-life family structure as the proxy of timing at 
infection to test our hypothesis in Sweden, a low-incidence area. A larger number of siblings 
and a later birth order may serve as indicators of earlier infection with EBV, and can lend 
insight into whether timing of primary infection with EBV is associated with subsequent risk 
of NPC [191].  
Further evaluation of risk factors for NPC in low-incidence populations will help to reveal 
differences and similarities in the pathogenesis of types I, II, and III NPC. For example, 
although infection with EBV is a sufficient cause for type III NPC, its role in type I is 
uncertain. Well established risk factors for type I NPC are smoking and alcohol drinking, 
while their roles in type III NPC are less clear. Previous studies in high-incidence areas 
provided little information on risk factors for type I NPC partly because of the limited 
number of cases (i.e. only ~1%) in high-incidence areas. Our study showed that the 
association with number of siblings among cases with type I NPC was weaker than among 
cases with undifferentiated NPC, although still positive and significant. Age at infection is 
not the only means through which other siblings could influence NPC risk. Birth order could 
be an indicator of exposure to other infectious agents, or associated with other exposures such 
as maternal breast feeding pattern and childhood nutrition [192, 193]. Nevertheless, our 
results suggested a positive association of larger sibship size, and later birth order with a 
higher risk of NPC. These NPC-specific findings contrast with data from other EBV-related 
disorders (i.e., IM and HL) [86, 194], highlighting possible differences in EBV-related risk 
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factors between the distinct tumor types that should be evaluated in a region such as 
Southeast Asia where NPC is an endemic disease. 
Oral Hygiene 
The association between poor oral health and risk of head and neck cancers has been 
extensive evaluated in studies with cohort design. However, it has not been evaluated for 
NPC, largely due to the limited number of NPC cases from a cohort study. Case-control 
design is more suitable to study the association for a rare disease. In this large scale 
population-based case-control study in NPC high-incidence populations in southern China, 
although a higher number of teeth lost was not associated with a higher NPC risk, excess 
risks were observed for other oral health indicators, such as a higher number of filled teeth. 
The association with earlier age at first adult tooth loss, albeit statistically non-significant, 
was in the same direction. In contrast, brushing teeth twice per day or more appeared to be 
inversely associated with NPC risk.  
To the best of our knowledge, this is the first population-based case-control study to address 
the association between poor oral health and NPC risk. Our findings are somewhat in line 
with those from a hospital-based study in Turkey [118], which showed that both infrequent 
tooth brushing and having more than 10 decayed teeth were associated with an elevated risk 
of NPC. The stronger associations in the Turkish study may be due to different study design, 
confounding factors, bias, chance, as well as the different oral hygiene condition in different 
populations.  
Although we found a null association between the number of adult teeth lost and risk of NPC, 
biologically plausible interpretations cannot be ruled out. In the present study, due to the 
relative younger ages of NPC onset in high-incidence populations (40-49 years), ~50% of 
study subjects had not experienced any adult tooth loss. Thus number of teeth lost may not be 
a sensitive indicator of oral health in this setting. Alternatively, the positive association with a 
higher number of filled teeth may suggest that factors related to dental caries are more 
important in the pathogenesis of NPC.  
Family History 
The more than 4-fold increase of NPC risk among first-degree relatives of NPC cases is in 
lines with that reported in other studies [33-36, 121, 122, 129, 130]. Results from high-
incidence areas consistently showed that the excess risk was only limited to family history of 
NPC but not to other non-NPC cancers. Whereas studies from intermediate- [34] and low-
incidence populations [36] showed that the elevated risk of NPC among first-degree relatives 
was not limited to NPC but extended to other cancers, such as cancer of the salivary glands 
and cervix. The underlying mechanisms are largely unknown. Such inconsistent findings 
could be explained by different penetrations of NPC susceptibility genes, or variations in 
attributable environmental or lifestyle risk factors, or both. In high-incidence area, 
environment risk factors alone are unlikely to contribute such strong familial associations. 
Studies have demonstrated the role of genetic risk factors in the pathogenies of NPC, such as 
certain HLA alleles [41, 42, 144].   
The present study also showed that the magnitude of association is stronger for people with a 
sibling history than with a parental history of NPC, and is also higher for people with a 
maternal history of NPC than a paternal history. These patterns could be explained by shared 
childhood environment between siblings, or similar dietary habits between mother and child. 
Our observation of slightly higher relative risks conferred by having an affected female than a 
male first-degree relative (i.e., a mother or sister as compared with a father or brother, 
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respectively) may be a chance finding, but it merits further investigation into possible 
mechanisms.    
In contrast to prior reports from China [122, 133], we found no significant modification of the 
association with family history of NPC by environmental risk factors. Our findings suggest 
that putative NPC susceptibility genes may act independently of environmental factors in 
NPC etiology. However, the small number of controls with a positive first-degree family 
history of NPC and the low power for heterogeneity test make it difficult to draw firm 
conclusions about the joint effects of family history and environmental risk factors. Pooled 
studies with larger numbers of study subjects will enable more powerful tests of such 
interactions.  
Different from other studies on family history, we used two complementary approaches to 
estimate the cumulative risk of NPC. They showed similar results, although each approach 
has its strength and limitation. Based on a case-control design, we were able to estimate the 
cumulative risk of NPC between ages 20 and 74 for people with a positive first-degree family 
history of NPC. We found that approximately 5.0% of men and 1.9% of women with a first-
degree family history of NPC will develop NPC, compared with 1.1% of men and 0.4% of 
women in the general population without such a history. If one was affected with NPC, 
he/she may be interested to know the cumulative risk for his/her first-degree relatives. We 
found 6.3% of NPC patients’ brothers and 3.5% of sisters up to age 74 years are expected to 
develop NPC, compared with 3.4% of fathers and 2.5% of mothers. These results could help 
to determine whether close clinical surveillance for NPC may be beneficial for individuals 
with a family history of NPC. 
6.1.2 Biomarkers for Early Detection and Screening 
The identification of disease biomarkers has two implications: it will not only help to identify 
markers that can distinguish patients from controls, but also help to provide new insights into 
the biology behind the disease: the selected eight proteins may highlight the important 
pathways in the carcinogenesis of NPC. For example, cyclin B is in the apoptosis pathway 
initiated by EBV-encoded LMP1 [195], which is necessary for the progression of the cells 
into and out of M phase of the cell cycle. Vascular endothelial growth factor (VEGF) is an 
important signaling protein involved in both vasculogenesis and angiogenesis, which was 
reported to be widely expressed in NPC specimens [196, 197]. In addition, the links between 
HAS1, LY6K, and NPC have not been explored before. Our findings may provide new 
mechanistic insight into the occurrence of NPC. 
The development of NPC is thought to involve a complex interplay between environmental 
risk factors, genetic susceptibility, and EBV infection. Previous studies largely focused on the 
search for EBV-related biomarkers, but paid less attention to the contributions from the host 
response. We hypothesized that the host response also plays an important role on the 
occurrence of NPC. Therefore, we aimed to validate previously reported human proteome 
and establish a panel of biomarkers that can facilitate early detection and prediction of NPC. 
The antibody suspension bead array assays, which have been developed for multiplex 
screening of a large number of proteins in patient cohorts, enable us to obtain the plasma 
antibody profile more efficiently. We found a panel of eight biomarkers that can achieve a 
promising result for early detection of NPC. Further studies are needed to develop more 
sensitive sandwich immunoassays for screening in larger sample sets, and test validity of the 
selected biomarkers.  
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6.2 METHODOLOGY ON EPIDEMIOLOGY 
6.2.1 Study Design 
To identify exposures involved in the development of a rare disease, a case-control design is 
more efficient than cohort design. For example, in a cohort study among 19,000 individuals 
conducted in an NPC high-incidence area, only 125 NPC cases were identified after an 
average of 17 years of follow-up [69]. In Taiwan, an NPC intermediate-incidence area, 
during a total of 185,587 person-years of follow-up, 33 incident NPC cases were identified 
from a community cohort comprising 9622 males [35]. In low-incidence area, such as 
Sweden, we followed about 5.3 million individuals between 1961 and 2009 to obtain a total 
of 301 NPC cases in Study I. For areas without established population registers, cohort 
design becomes logistically impractical. In addition, for exposure with a small effect size, a 
large sample size is required to achieve a satisfied statistical power. Sample size is expected 
to be increased substantially when studying the joint effects of exposures. Conceptually, 
cohort study design is ideal to address the association between exposure and disease because 
the exposure information of all individuals in a source population is collected before disease 
occurrence. Nevertheless, complex diseases such as most types of cancers are thought to 
involve a complex interplay between environmental factors and genetic susceptibility; the 
effect size of each individual exposure is usually small. Case-control design becomes the only 
possible alternative. 
Ideally, a case-control study should include all incident cases of the disease under study in a 
defined population during a specified time period. Under this conceptualization, it requires an 
existing registry to keep the defined population under surveillance. In the majority of settings 
around the globe, these fundamental requirements are difficult or impossible to 
accommodate. In addition, a group of controls without the disease are sampled directly from 
this source population in such a way (generally randomly) that they inform about the estimate 
of the prevalence of the exposure and covariates in the person-time that give rise to the cases. 
As a corollary, many epidemiologic researches are undertaken with suboptimal methods, 
such as hospital-based and neighborhood-based studies. By using these study designs, 
information on environmental exposures (particularly with regard to diet, smoking, and 
medical history) collected is not representative. Even worse, a population and person-time 
cannot be clearly defined in many case-control studies, leading important human diseases to 
escape proper investigation of their causes altogether.  
For NPC, few strictly population-based case-control studies have as yet been conducted in 
mainland China [123, 198]. Study II and study III are based on a population-based case-
control study in southern China, where the registries (only available in two counties) do not 
cover the entire population of the study area. We have provided an example of how 
population-based epidemiologic research can be successfully conducted in southern China. 
We took enormous efforts to estimate total number of incident cases in the source population, 
develop a rapid case ascertainment system, contact randomly selected controls, and collect 
questionnaire data and biosamples. The overall participating rate of about 85% demonstrated 
the feasibility of conducting rigorous population-based case-control study in mainland China.  
6.2.2 Validity  
There are two components of the validity of a study: internal validity and external validity 
(also known as generalizability). For internal validity, most violations can be classified into 
three categories: confounding, selection bias, and information bias.  
Confounding 
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Missing information on important confounders is one of the major limitations of studies 
conducted based on population registers. In study I, although we observed an increased risk 
of NPC with a larger number of total siblings and number of older siblings, the associations 
could be confounded by other potential confounding factors, such as day care attendance, 
breast feeding, social economic status, and smoking. In study II, information on receipt of 
professional dental care was not available, which precluded accounting for this potential 
confounder. There is no formal statistical test to examine whether one potential factor can 
actually confound an association between exposure of interest and outcome; a lot of 
approaches, such as directed acyclic graph, are largely based on prior knowledge. However, 
our knowledge in etiology is usually limited, thus the association we found for observational 
study cannot be interpreted as the causation.  
Selection Bias 
Selection bias is one of the major concerns in observational studies, and it causes either an 
over- or under- estimated association. For example, in study I, it is possible that the bias 
could occur because we “select” NPC cases and IM cases who had had a recorded diagnosis 
in registers. Because the Swedish Cancer Register is essentially complete, however, it is 
unlikely that such a selection bias would occur in this NPC study. For IM, we cannot rule out 
the possibility that the inverse association was limited to those hospitalized IM cases. 
However, a recent study based on a similar study setting in Denmark [86] has reported 
similar results irrespective of whether hospitalized or self-reported IM was treated as the 
outcome. We thus considered this scenario is very rare. In study II, although the case-control 
study has reached a high participating rate among controls (~85%), we cannot rule out the 
possibility that lower-socioeconomic status (SES) controls with poorer oral health and 
hygiene were more likely to participate than higher-SES controls who could not be contacted 
due to employment outside of their hometown. Therefore, in this case, selection bias favoring 
underestimated ORs could have occurred. In study III, if controls who were positive for 
family history were more likely to participate in an epidemiological research on cancer, that 
would lead to a biased estimate on the prevalence of a positive family history of study 
population. In study IV, selection bias may also occur because blood samples were available 
among less than 50% of the parent case-control study. However, because the distributions of 
age and sex were similar among those with samples and those without, we believe that 
selection bias occurred due to the unavailability of the samples, if any, should be minimal.   
Information Bias (misclassification) 
In this thesis, information bias of outcome is less likely to occur because the diagnosis of 
cases was either based on Swedish Cancer Register or histopathological confirmed. 
Information bias of exposure is one of the major concerns in the four studies. First, in study I, 
the Multi-Generation Register is incomplete for some individuals, which could result in 
differential misclassification if the probability of missing data differed between cases and 
controls [157]. However, our sensitivity analyses restricted by birth date or diagnosis date 
suggested that such bias, if any, was minimal. In addition, we selected sibship size and birth 
order as the proxy of timing at infection with EBV, a more direct measure of timing at 
infection with EBV thus is needed to clarify the misclassification of the exposure. Second, in 
study II, we lacked information on disease symptoms and stage, which may influence some 
oral health and hygiene measures [199]. If cases were more likely to report a poor oral 
hygiene due to the presence of the disease, it may lead to an over-estimated association. It 
may be the same case for study III that cases were more likely to report a positive family 
history of NPC than controls. Therefore, we tried to validate self-reported family history of 
NPC, although the results were based on only one county, and may not be able to be 
generalized to other study regions. We also limited the primary analysis to first-degree 
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relatives to reduce recall bias. The results of our validation study showed that ORs and 
cumulative risks would be overestimated suggesting that information bias exits. Nevertheless, 
the striking positive association persisted after adjustment for bias. Third, in study IV, 
biomarkers were measured retrospectively using long term stored samples (collected in 1990s 
and assayed in 2016), thus we cannot rule out the possibility that results were biased due to 
the degradation of proteome. Assuming the biomarkers degraded at a similar rate, it may lead 
to an underestimate (dilution) of the true strength of an association between the biomarker 
with the risk of NPC. Cross-reaction between proteins resulting from a similar structure or 
amino acid sequence to our proteins of interest cannot be ruled out, and this may lead to a 
false positive results. In addition, due to the complex structure of the proteins, we may fail to 
target the specific domain and the true functionally relevant protein if with a low 
concentration it could be masked by a non-functional protein with a high concentration, thus 
resulting in a false negative finding. 
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7 CONCLUSIONS 
 
• In low-incidence areas, the risk of developing NPC increased among individuals with 
more siblings, especially older siblings, whereas the risk of developing IM decreased 
with increasing number of siblings (either younger or older). Childhood social 
enviroments, especially that associated with an earlier EBV infection, may play a 
possible pathogenic role in NPC.  
• In high-incidence areas, poor oral health may be associated with an elevated risk of NPC, 
although some associations may be affected by residual confounding of smoking. 
Prospective cohort design with a more comprehensive measure of oral hygiene 
conditions could help to clarify the question of whether poor oral health has an important 
role of NPC development.  
• In high-incidence areas, a positive first-degree family history of NPC is associated with a 
4-fold increase in risk of NPC. The excess risk was higher for individuals with an 
affected sibling than for those with an affected parent. The absolute risks quantified, 
along with results of future studies on other risk stratification factors and cost-benefit 
analyses, may guide the clinical consultation and development of surveillance policies 
for this important public health problem in NPC-endemic areas. 
• The mulitplex screening of a large number of proteins by antibody suspension bead 
assays is a powerful method that could identify human proteomic markers for early 
detection of NPC in additon to EBV-related biomarkers. The validity of the diagnositc 
performance of selecetd biomarkers is awating further invesitgation.   
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8 FUTURE PERSPECTIVES 
8.1 FOR EPIDEMIOLOGY 
Field work training is an essential part for the discipline of epidemiology, whereas it has 
become less and less available in many training programs. Rigorous epidemiological study 
design is the key to obtaining unbiased measures for successful scientific research. In NPC 
research field, however, partly due to the fact that it is endemic in less developed areas, 
proper facilities (e.g. population register) are lacked to conduct high quality studies. We hope 
our study can provide an example which will encourage others to undertake similar studies 
(although not limited to NPC) in populations with similar characteristics. To understand the 
complexity of etiology, pooling analysis of a few high quality studies is necessary.  
8.2 FOR ETIOLOGY AND EARLY DETECTION  
A very intriguing question is why almost of all people are infected with EBV, but only some 
of the infections result in NPC, whereas some others result in HL, BL, and EBV positive 
gastric cancer. It seems that different populations are susceptible to different types of cancers. 
For example, areas with a high-incidence of NPC always have a low-incidence of HL, and 
vice versa. EBV alone is not a sufficient cause of the cancers, and it requires co-factors to act 
together and contribute the cancer development.  
Few studies have tried to address the research question by comparing the etiology across 
EBV-related cancers. In fact, different risk patterns can be observed for different EBV-related 
cancers. For example, it seems that IgA response is more important for NPC whereas IgG 
response is more important for HL [200]. This cumulative evidence highlights that the 
immune response of host to EBV infection could be critical in explaining the differential risk 
of developing these EBV-related tumors. However, comprehensive EBV antibody patterns 
have not been investigated to date. Previous studies of NPC have evaluated both IgG and IgA 
antibodies against 3 EBV proteins, including EBNA1, VCA, and EA [200].  Although the 
evidence is strong for a prospective association between NPC risk and EBV-specific 
antibodies, in particular IgA antibodies, these 3 proteins represent only a small fraction of the 
approximately 100 open reading frames for EBV. The data evaluating an association between 
the antibody responses to EBV and HL is even more limited, with only one prospective study 
specific to EBV-positive HL. Expanding the number of antigens to be evaluated in epithelial 
and lymphoid tumors in parallel could help to fill this gap and elucidate the role of the 
immune response to EBV infection in the development of distinct EBV-associated cancers.  
 
Greater EBV genetic diversity other than a few EBV genes such as LMP1, EBNA1, and 
BZLF1 has been observed [201, 202]. With the development of next-generation sequencing 
technology, we will be able to sequence the whole genome of EBV in a large sample size. 
Full characterization of viral diversity will help us to understand the patterns of EBV genetic 
variation and their associations with cancers in different populations.  
There are five phases of a biomarker development for early detection of cancer [203]. For 
NPC, we lacked longitudinally collected samples and randomized controlled trial design to 
evaluate the true value of biomarkers in the secondary prevention of NPC. More and more 
large cohort studies with biobanking have been established recently, at least in China. In the 
future, we may be able to utilize these samples and overcome the limitations of evaluating 
biomarker only based on cross-sectional samples.     
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